Biocompatibles announces new deals and funding plans in a busy week
This article was originally published in Clinica
Last week Biocompatibles announced it had formed an R&D deal with Boston Scientific, established eight distribution agreements for its DivYsio coronary stents and announced plans to secure £29 million ($47 million) in funding for the next year.
You may also be interested in...
Hours before the US FDA confirmed the first drug shortage due to active pharmaceutical ingredient constraints because of the coronavirus situation in China, generics industry leader Mylan came under pressure about the potential impact on its business.
Government advisory committee gives initial nod to what will become Japan’s most expensive single drug, but reimbursement pricing could come in for close scrutiny.
Laparoscopic power morcellation to remove uterine fibroids should only be performed with the use of a compatible containment system, and only on women younger than 50, the US FDA said in a newly published safety communication and draft guidance document. See what the president of the gynecologic trade group AAGL, Jubilee Brown, said about it here.